NCT00770354 - Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2011

Conditions

Breast Carcinoma

Interventions

DRUG

AS1402

A complete treatment cycle spans 28 days. Patients randomised to AS1402 will receive a 1-hour infusion of 9 mg/kg on day 1, 8, 15 and 22 of each cycle. Patients will receive letrozole (2.5 mg daily tablet).

DRUG

Letrozole

Daily 2.5 mg oral letrozole tablet

Trial Locations (2)

357500

State Medical Institution, Pyatigorsk

454087

State Therapeutical and Prophylactic Institution: Chelyabinsk Regional Oncological Center, Chelyabinsk